1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. RISING GOVERNMENT INITIATIVES
3.2.2. GROWING PERVASIVENESS OF CANCER CASES IN OLDER POPULACE
3.2.3. GROWING NUMBER OF DIAGNOSTIC CENTERS
3.2.4. GROWTH OF PRECISION MEDICINE
3.2.5. EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
3.2.6. RISING POTENTIAL OF THE LIQUID BIOPSY
3.2.7. TECHNOLOGICAL ADVANCEMENT
3.3. KEY RESTRAINTS
3.3.1. LACK OF CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
3.3.2. POOR COMPENSATION STRUCTURES
3.3.3. HIGH COST OF THE TEST
3.3.4. LACK OF REIMBURSEMENT
3.3.5. LACK OF SKILLED PROFESSIONALS

4. KEY ANALYTICS
4.1. PORTER'S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER'S POWER
4.1.4. SUPPLIER'S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. KEY LIQUID BIOPSY INITIATIVES
4.3. REGULATORY FRAMEWORK
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY INVESTMENT INSIGHTS

5. MARKET BY THERAPEUTIC APPLICATION
5.1. LUNG CANCER
5.2. BREAST CANCER
5.3. PROSTATE CANCER
5.4. COLORECTAL CANCER
5.5. MELANOMA CANCER
5.6. OTHER TYPES OF CANCER
5.7. NON-ONCOLOGY APPLICATION

6. MARKET BY CLINICAL APPLICATION
6.1. TREATMENT MONITORING
6.2. PROGNOSIS AND REOCCURRENCE MONITORING
6.3. TREATMENT SELECTION
6.4. DIAGNOSIS AND SCREENING

7. MARKET BY BIOMARKER TYPE
7.1. NUCLEIC ACID
7.2. PROTEIN
7.3. EXTRACELLULAR VESICLES
7.4. CELLS

8. MARKET BY ANALYSIS PLATFORM
8.1. NGS
8.2. MICROARRAY
8.3. PCR
8.4. PROTEOMICS
8.5. OTHER ANALYSIS PLATFORMS

9. MARKET BY ANALYSIS PURPOSE
9.1. EARLY DETECTION/SCREENING
9.2. THERAPY GUIDANCE
9.3. MONITORING
9.4. DIAGNOSIS

10. MARKET BY PRODUCT
10.1. CIRCULATING TUMOR DNA (CTDNA)
10.2. CIRCULATING TUMOR CELLS (CTCS)
10.3. CELL-FREE DNA (CFDNA)
10.4. EXTRACELLULAR VESICLES AND OTHERS

11. MARKET BY END-USER
11.1. PHYSICIANS' OFFICE LABORATORIES
11.2. HOSPITALS
11.3. CLINICAL DIAGNOSTIC LABORATORIES

12. GEOGRAPHICAL ANALYSIS
12.1. NORTH AMERICA
12.1.1. THE UNITED STATES
12.1.2. CANADA
12.2. EUROPE
12.2.1. THE UNITED KINGDOM
12.2.2. FRANCE
12.2.3. GERMANY
12.2.4. ITALY
12.2.5. RUSSIA
12.2.6. BELGIUM
12.2.7. POLAND
12.2.8. REST OF EUROPE
12.3. ASIA PACIFIC
12.3.1. JAPAN
12.3.2. CHINA
12.3.3. INDIA
12.3.4. SOUTH KOREA
12.3.5. AUSTRALIA & NEW ZEALAND
12.3.6. THAILAND
12.3.7. INDONESIA
12.3.8. VIETNAM
12.3.9. REST OF ASIA PACIFIC
12.4. REST OF WORLD
12.4.1. LATIN AMERICA
12.4.2. MIDDLE EAST & AFRICA

13. COMPANY PROFILES
13.1. BECTON DICKINSON AND COMPANY (BD)
13.2. F HOFFMANN-LA ROCHE
13.3. BIO-RAD LABORATORIES INC
13.4. B BRAUN MELSUNGEN AG
13.5. BOSTON SCIENTIFIC CORPORATION
13.6. QIAGEN NV
13.7. PLANMECA OY
13.8. COOK MEDICAL INC
13.9. AD-TECH MEDICAL INSTRUMENT CORP
13.10. AGILENT TECHNOLOGIES INC
13.11. ARGON MEDICAL DEVICES INC
13.12. CINTEC MEDICAL LTD
13.13. FISCHER MEDICAL TECHNOLOGIES LLC
13.14. IMS INTERNAZIONALE MEDICO SCIENTIFICA SRL